Pharmaceuticals in Asia-Pacific

Date: June 30, 2017
Pages: 35
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P6A3660DC7FEN
Leaflet:

Download PDF Leaflet

Pharmaceuticals in Asia-Pacific
Pharmaceuticals in Asia-Pacific

SUMMARY

Pharmaceuticals in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the Asia-Pacific pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

KEY HIGHLIGHTS
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
  • The Asia-Pacific pharmaceuticals market had total revenues of $276.4bn in 2016, representing a compound annual growth rate (CAGR) of 6.4% between 2012 and 2016.
  • The regional market is dominated by the Chinese, which is also proving to be a major growth area due to rising incomes and a greater emphasis placed on healthcare. However, the Chinese market is quite fragmented, making it more attractive to foreign and domestic companies to consolidate through merger and acquisition.
  • Although certain markets such as China, India and Indonesia are growing at a fast pace, more mature markets such as South Korea and Japan are not. Governments are keen to keep costs down as the healthcare demands from an aging population grow. Greater emphasis is being placed on generic drugs and pharmaceutical companies are under public pressure to provide cost effective drugs.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Asia-Pacific
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Asia-Pacific
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific pharmaceuticals market with five year forecasts
REASONS TO BUY
  • What was the size of the Asia-Pacific pharmaceuticals market by value in 2016?
  • What will be the size of the Asia-Pacific pharmaceuticals market in 2021?
  • What factors are affecting the strength of competition in the Asia-Pacific pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in Asia-Pacific's pharmaceuticals market?
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Daiichi Sankyo Co., Ltd.
Shanghai Pharmaceuticals Holding Co Ltd
Takeda Pharmaceutical Company Limited
Yangtze River Pharmaceutical Group
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Asia-Pacific pharmaceuticals market value: $ billion, 2012–16
Table 2: Asia–Pacific pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: Asia-Pacific pharmaceuticals market share: % share, by value, 2016
Table 4: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: Daiichi Sankyo Co., Ltd.: key facts
Table 6: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 7: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 8: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 9: Shanghai Pharmaceuticals Holding Co Ltd: key facts
Table 10: Shanghai Pharmaceuticals Holding Co Ltd: key financials ($)
Table 11: Shanghai Pharmaceuticals Holding Co Ltd: key financials (CNY)
Table 12: Shanghai Pharmaceuticals Holding Co Ltd: key financial ratios
Table 13: Takeda Pharmaceutical Company Limited: key facts
Table 14: Takeda Pharmaceutical Company Limited: key financials ($)
Table 15: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 16: Takeda Pharmaceutical Company Limited: key financial ratios
Table 17: Yangtze River Pharmaceutical Group: key facts

LIST OF FIGURES

Figure 1: Asia-Pacific pharmaceuticals market value: $ billion, 2012–16
Figure 2: Asia–Pacific pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: Asia-Pacific pharmaceuticals market share: % share, by value, 2016
Figure 4: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2016
Figure 6: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2016
Figure 7: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2016
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2016
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2016
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2016
Figure 11: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 12: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 13: Shanghai Pharmaceuticals Holding Co Ltd: revenues & profitability
Figure 14: Shanghai Pharmaceuticals Holding Co Ltd: assets & liabilities
Figure 15: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 16: Takeda Pharmaceutical Company Limited: assets & liabilities

COMPANIES MENTIONED

Daiichi Sankyo Co., Ltd.
Shanghai Pharmaceuticals Holding Co Ltd
Takeda Pharmaceutical Company Limited
Yangtze River Pharmaceutical Group
Skip to top


OTC Pharmaceuticals in Asia-Pacific US$ 350.00 Sep, 2016 · 36 pages

Ask Your Question

Pharmaceuticals in Asia-Pacific
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: